0001520138-21-000140.txt : 20210303 0001520138-21-000140.hdr.sgml : 20210303 20210302183249 ACCESSION NUMBER: 0001520138-21-000140 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kallo Inc. CENTRAL INDEX KEY: 0001389034 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 980542529 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53183 FILM NUMBER: 21705895 BUSINESS ADDRESS: STREET 1: 255 DUNCAN MILLS ROAD STREET 2: SUITE 504 CITY: TORONTO STATE: A6 ZIP: M3B 3H9 BUSINESS PHONE: (416) 246-9997 MAIL ADDRESS: STREET 1: 255 DUNCAN MILLS ROAD STREET 2: SUITE 504 CITY: TORONTO STATE: A6 ZIP: M3B 3H9 FORMER COMPANY: FORMER CONFORMED NAME: Diamond Technologies Inc. DATE OF NAME CHANGE: 20091203 FORMER COMPANY: FORMER CONFORMED NAME: Printing Components Inc. DATE OF NAME CHANGE: 20070206 10-Q 1 kalo-20200331_10q.htm FORM 10-Q FOR PERIOD ENDING MARCH 31, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020
OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53183

KALLO INC.

(Exact name of registrant as specified in its charter)

NEVADA

(State or other jurisdiction of incorporation or organization)

255 Duncan Mill Road,

Suite 504

Toronto, Ontario

Canada M3B 3H9

(Address of principal executive offices, including zip code.)

(416) 246-9997

(Registrant’s telephone number, including area code)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	o	Accelerated Filer	o
Non-accelerated Filer	o	Smaller Reporting Company	x
Emerging Growth Company	o
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES x NO o

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicated the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 1,147,698,199 as of January 31, 2021.

KALLO INC.

MARCH 31, 2020

TABLE OF CONTENTS

		PAGE

*PART I*

Item 1.	Financial Statements.	3

	Unaudited Consolidated Balance Sheets	3

	Unaudited Consolidated Statements Of Operations	4

	Unaudited Consolidated Statements Of Changes In Stockholders’ Deficiency	5

	Unaudited Consolidated Statements Of Cash Flows	6

	Notes to Unaudited Consolidated Financial Statements	7

	Forward-Looking Statements	12

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	13

Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	20

Item 4.	Controls and Procedures.	20

*PART II*

Item 1.	Legal Proceedings.	20

Item 1A.	Risk Factors.	21

Item 6.	Exhibits.	24

Signatures		27

Exhibit Index		28

-2-

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS.

KALLO INC.

Consolidated Balance Sheets

(Amounts expressed in US dollars)

(Unaudited)

	March 31,			December 31,
ASSETS	2020			2019
Current Assets:
Total Current Assets	$	—		$	—

TOTAL ASSETS	$	—		$	—

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
Current Liabilities:
Accounts payable and accrued liabilities		3,665,380			3,860,499
Convertible loans payable – third parties		271,412			265,217
Short term loans payable		65,236			66,521
Convertible loans payable – related parties		928,683			907,132
Liability for issuable shares		1,724,290			1,724,290
Total Current Liabilities		6,655,001			6,823,659
TOTAL LIABILITIES		6,655,001			6,823,659

Commitments and Contingencies (Note 7)

Stockholders’ Deficiency
Preferred stock, $0.00001 par value, 100,000,000 shares authorized, 95,000,000 Series A preferred shares issued and outstanding		950			950
Common stock, $0.00001 par value, 1,150,000,000 shares authorized, 1,147,698,199 and 1,147,698,199 shares issued and outstanding, respectively.		11,478			11,478
Additional paid-in capital		41,920,116			41,920,116
Assignment of liabilities		(3,455,111	)		(3,462,554	)
Accumulated deficit		(45,132,434	)		(45,293,649	)

Total Stockholders’ Deficiency		(6,655,001	)		(6,823,659	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	—		$	—

See accompanying notes to the unaudited consolidated financial statements

-3-

Table of Contents

KALLO INC.

Consolidated Statements of Operations

(Amounts expressed in US dollars)

(Unaudited)

	Three months Ended
	March 31,
	2020			2019

Operating Expenses
General and administration	$	98,699		$	1,711,474
Selling and marketing		18,563			1,086
Operating loss		(117,262	)		(1,712,560	)

Interest and financing costs		(27,746	)		(27,442	)
Foreign exchange (loss) gain		306,223			(64,736	)

Net Income (Loss)	$	161,215		$	(1,804,738	)

Basic and diluted net loss per share	$	0.00		$	(0.00	)

Weighted average shares used in calculating Basic and diluted net loss per share		1,147,698,199			1,147,698,199

See accompanying notes to the unaudited consolidated financial statements

-4-

Table of Contents

KALLO INC.

Consolidated Statements of Changes in Stockholders’ Deficiency

For the three months ended March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

														Deficit
														Accumulated			Total
	Preferred Stock				Common Stock				Additional		Assignment			During the			Stockholders’
	$.00001 par value				$.00001 par value				Paid-In		Of			Development			Equity
	Shares		Amount		Shares		Amount		Capital		Liabilities			Stage			(Deficit)

Balance December 31, 2019		95,000,000		950		1,147,698,199		11,478		41,920,116		(3,462,554	)		(45,293,649	)		(6,823,659	)
Cash settlement of liabilities		—		—		—		—		—		7,443			—			7,443
Net income		—		—		—		—		—		—			161,215			161,215
Balance March 31, 2020		95,000,000	$	950		1,147,698,199	$	11,478	$	41,920,116	$	(3,455,111	)	$	(45,132,434	)	$	(6,655,001	)

See accompanying notes to the unaudited consolidated financial statements

-5-

Table of Contents

KALLO INC.

Consolidated Statements of Cash Flows

(Amounts expressed in US dollars)

(Unaudited)

	Three months Ended
	March 31,
	2020			2019

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	161,215		$	(1,804,738	)
Adjustment to reconcile net loss to cash used in operating activities:
Stock based compensation		—			1,574,480
Interest and penalties		27,746			27,442
Unrealized foreign exchange loss (gain)		(310,231	)		64,984
Changes in operating assets and liabilities:
Increase (decrease) in accounts payable and accrued liabilities		121,070			111,489
NET CASH USED IN OPERATING ACTIVITIES		(200	)		(26,343	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from short term loans payable		200			26,343
NET CASH PROVIDED BY FINANCING ACTIVITIES		200			26,343

NET (DECREASE) INCREASE IN CASH		—			—
CASH - BEGINNING OF PERIOD		—			—
CASH - END OF PERIOD	$	—		$	—
SUPPLEMENTAL CASH FLOW INFORMATION
Income tax paid	$	—		$	—
Interest paid	$	—		$	—
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Settlement of accounts payable by FE Pharmacy, Inc.	$	7,443		$	56,415

See accompanying notes to the unaudited consolidated financial statements

-6-

Table of Contents

KALLO INC.

Notes to Consolidated Financial Statements

March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

NOTE 1 – BUSINESS AND GOING CONCERN

Organization

Kallo Inc. (“Kallo” or the “Company”) develops customized health care solutions designed to improve or enhance the delivery of care in the countries and regions we serve.

Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The amounts of assets and liabilities in the consolidated financial statements do not purport to represent realizable or settlement values. The Company has incurred operating losses since inception and has an accumulated deficit and a working capital deficit at March 31, 2020. The Company is expected to incur additional losses as it executes its go to market strategy. This raises substantial doubt about the Company’s ability to continue as a going concern.

The Company has met its historical working capital requirements from the sale of common shares and short term loans. In order to not burden the Company, the officer/stockholder has agreed to provide funding to the Company to pay its annual audit fees, filing costs and legal fees as long as the board of directors deems it necessary. However, there can be no assurance that such financial support shall be ongoing or available on terms or conditions acceptable to the Company. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS

Basis of Presentation

The accompanying unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These unaudited consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes, which are included as part of the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.

Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year ended December 31, 2019 as reported in the 10-K have been omitted. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited consolidated financial statements.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires the use of a new current expected credit loss (“CECL”) model in estimating allowances for doubtful accounts with respect to accounts receivable. Receivables from revenue transactions, or trade receivables, are recognized when the corresponding revenue is recognized under ASC Topic 606, Revenue from Contracts with Customers. The CECL model requires that the Company estimate its lifetime expected credit loss with respect to these receivables and record allowances that when deducted from the balance of the receivables, represent the estimated net amounts expected to be collected. Given the generally short term nature of trade receivables, we do not apply a discounted cash flow methodology. However, the Company considers whether historical loss rates are consistent with expectations of forward-looking estimates for our trade receivables. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures.

-7-

Table of Contents

KALLO INC.

Notes to Consolidated Financial Statements

March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS (continued)

Recently Issued Accounting Pronouncements

On December 18, 2019 the FASB issued the ASU 2019-12 “Income taxes (Topic 740)—Simplifying the accounting for income taxes”. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is assessing the effects that the adoption of this accounting pronouncement may have on its financial statements.

NOTE 3 – COMMON STOCK

During the three months ended March 31, 2020, there were no movements in share capital issued and outstanding.

On April 8, 2017, the Company entered into an agreement with FE Pharmacy Inc., a company controlled by a shareholder of Kallo, and a related party, whereby in consideration for the issuance of 475,000,000 common stock of Kallo, FE Pharmacy Inc. assumed and will pay all of the Company’s outstanding indebtedness as at April 7, 2017. The 475,000,000 shares issuable to FE Pharmacy Inc. has been valued at the book value of the total liabilities assigned to FE Pharmacy Inc. of $4,135,037. The assignment of the liabilities to FE Pharmacy Inc. has been recorded as a receivable in the equity section of the consolidated balance sheet and will be reduced as the liabilities are settled by FE Pharmacy Inc. During the three months ended March 31, 2020, the assignment of liabilities amount has been reduced by $7,443 cash settlement of accounts payable.

NOTE 4 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2019, the Board of Directors approved the issuance of 57,000,000 shares to directors and shareholders of the Company for par value of $570, resulting in as stock-based compensation valued at $1,373,130. These shares will be issued after the Company is able to increase its authorized number of common shares.

During the year ended December 31, 2019, the Company designated 5,000,000 of is preferred stock as Series B preferred stock, each of which has 1,000 votes and are not convertible. The Company, will not, without the approval or express written consent of the all the holders of the Series B preferred stock (i) establish, create, authorize or approve the issuance of any series or class of preferred stock (ii) change any of the rights, privileges or preferences of the Series B preferred stock or (iii) redeem the Series B preferred stock..

During the year ended December 31, 2019, the Board of Directors approved the issuance of 5,000,000 Series B preferred shares to a director as compensation for services rendered and their fair value were deemed to be $201,350 based on the voting rights of the preferred shares relative to the fair value of the Company at the date of the approved issuance. These shares will be issued after the Company becomes current on all its filings requirements.

Included in liability for issuable shares is 3,731,005 common shares valued at $149,240 and approved for issuance to a family of the controlling shareholder of FE Pharmacy Inc as compensation during 2018 which will be issued after the Company is able to increase its authorized number of common shares. The transfer agent has erroneously issued these shares in spite of the Company’s instructions to wait for the increase in authorized number of common shares.

Included in accounts payable and accrued liabilities is an amount of $1,310,980 (December 31, 2019 - $1,332,488) due to directors of the Company as of March 31, 2020.

Included in convertible loans payable to related parties is an amount of $928,683 (December 31, 2019 - $907,132), including accrued interest, owing to a director and a shareholder of the Company as of March 31, 2020.

Included in short term loans payable is an amount of $49,889 (December 31, 2019 - $49,758) due to the controlling shareholder of FE Pharmacy Inc. and a related party as at March 31, 2020.

-8-

Table of Contents

KALLO INC.

Notes to Consolidated Financial Statements

March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

NOTE 5 – CONVERTIBLE LOANS PAYABLE

	March 31, 2020		December 31, 2019

Convertible promissory notes bearing interest at 15% per annum – third parties	$	271,412	$	265,217
Convertible promissory notes bearing interest at 15% per annum – related parties		928,683		907,132
	$	1,200,095	$	1,172,349

The Convertible loans payable bear 15% interest per annum and are convertible at a fixed price at any time during their 1 year term. The Company has the option to pay the note at any time. The Company analyzed the conversion option for derivative accounting consideration under ASC Topic 815-40, Derivatives and Hedging – Contract in Entity’s Own Stock and concluded that the embedded conversion was a derivative but the fair value of the feature was zero. The total outstanding notes is $1,200,095, including accrued interest, of which $928,683 is to from related parties. Interest of $27,746 on the convertible loans payable are included in net finance charge for the three months ended March 31, 2020 included in the consolidated statement of operations. All of the above convertible loans payable were in default as of March 31, 2020.

NOTE 6 – SHORT TERM LOANS PAYABLE

	March 31, 2020		December 31, 2019

Non-interest bearing short term funding from third party	$	15,347	$	16,763
Non-interest bearing short term funding from related party		49,889		49,758
	$	65,236	$	66,521

As of March 31, 2020, the balance of $65,236 represented short term funding provided by a third party and a related party which are non-interest bearing, unsecured and have no fixed repayment date. The loan from third party in Canadian dollars is $21,772 which is subject to revaluation at the end of each quarter.

-9-

Table of Contents

KALLO INC.

Notes to Consolidated Financial Statements

March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Contingencies

On April 21, 2017, an ex-employee of Kallo obtained a judgement ordering Kallo to pay Canadian $ 135,959 for unpaid wages and expenses relating to services performed in 2016. The full amount has been accrued for in the financial statements of Kallo.

On October 24, 2016, a consultant obtained a judgement ordering Kallo to pay Canadian $34,924 for unpaid fees. The full amount has been accrued for in the financial statements of Kallo.

On October 6, 2017, Thornley Fallis Communications Inc. (“Thornley”) commenced a third party claim against Kallo concerning monies that Kallo allegedly owed to Thornley for redesign of a website and public relation services. Thornley is seeking damages in the amount of Canadian $169,345 plus interest on the amounts outstanding and indemnification of the costs of the action. An amount of Canadian $134,960 has been accrued for in the financial statements of Kallo.

There is also a claim by Commercial Credit Adjusters on behalf of Northwest Company for payment of Canadian $34,000. An amount of Canadian $24,016 has been accrued for in the financial statements of Kallo. Negotiations are in process for the settlement of this debt for a lump sum.

Canada Revenue Agency has assessed the Company for unpaid Canadian $77,664 as at March 31, 2020 representing unremitted employee source deductions and related penalties and interest, the full amount of which has been accrued in the financial statements of Kallo.

Responsibility for payments of the above claims has been assumed by FE Pharmacy Inc. under the terms of the agreement mentioned in Note 3.

NOTE 8 – SUBSEQUENT EVENTS

On December 11, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the State of Eritrea (the “Ministry”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, the Ministry is seeking to borrow the sum of 521,437,477 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 521,437,477 Euros in four equal instalments. After receiving its share of the instalments payment, Kallo Inc. will deliver 25,000,000 Euros of each payment to the Ministry’s National Food Security Program.

On December 10, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the Republic of Mozambique (“Mozambique”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, Mozambique is seeking to borrow the sum of 1,305,256,575 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 1,305,256,575 Euros in four equal instalments. After receiving its share of the instalments payment, Kallo Inc. will then deliver 125,000,000 Euros of each payment to the Ministry’s National Food Security Program.

On November 30, 2020, the Company finalized with the Ministry of Health and the Ministry of Finance of the Federal Democratic Republic of Ethiopia (the “Borrower”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, the Borrower is seeking to borrow the sum of 2,459,817,336 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 2,459,817,336 Euros in four equal instalments to the Borrower, of which 1,860,437,075 Euros is to be used in connection with the National Healthcare Infrastructure program. After receiving its share of the instalments payment, Kallo Inc. will then deliver 125,000,000 Euros of each instalment payment received to the Borrower’s National Food Security Program.

-10-

Table of Contents

KALLO INC.

Notes to Consolidated Financial Statements

March 31, 2020

(Amounts expressed in US dollars)

(Unaudited)

NOTE 8 – SUBSEQUENT EVENTS (continued)

On November 10, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the Kingdom of Eswatini (“Eswatini”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, Eswatini is seeking to borrow the sum of 549,978,787 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 549,978,787 Euros in four equal instalments to Kallo Inc and the Company will deliver 75,000,000 Euros of each payment to Eswatini’s National Food Security Program.

On June 26, 2020, the Company finalized contracts with the Republic of Kenya (“Kenya”) and Techno-Investment Module Limited (“TIM”) for a Project Contract and a Finance Contract. Under the terms of the Agreement, Kenya is seeking to borrow the sum of 1,068,932,543 Euros from TIM and the funds are to be used primarily to build phase one of a planned National Healthcare Infrastructure in the Republic of Kenya to be undertaken by Kallo Inc. In accordance with the Finance Contract, Kallo Inc. may receive up to four payments of 40,261,253 Euros in consideration for the goods and services that the Company is to provide under the Project Contract.

-11-

Table of Contents

As used herein, the term “we,” “us,” “our,” and the “Company” refers to Kallo, Inc. a Nevada corporation.

FORWARD-LOOKING STATEMENTS

THIS FORM 10-Q CONTAINS “FORWARD-LOOKING STATEMENTS”. FORWARD-LOOKING STATEMENTS ARE STATEMENTS CONCERNING ESTIMATES, PLANS, OBJECTIVES, GOALS, STRATEGIES, EXPECTATIONS, INTENTIONS, PROJECTIONS, DEVELOPMENTS, FUTURE EVENTS, PERFORMANCE OR PRODUCTS, UNDERLYING (EXPRESSED OR IMPLIED) ASUMPTIONS AND OTHER STATEMENTS THAT ARE OTHER THAN HISTORICAL FACTS. IN SOME CASES FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING WORDS SUCH AS “ESTIMATED,” “BELIEVES,” “EXPECTS,” “MAY,” “WILL,” “SHOULD,” OR “ANTICIPATES,” OR THE NEGATIVE OF THESE WORDS OR OTHER VARIATIONS OF THESE WORDS OR COMPARABLE WORDS, OR BY DISCUSSIONS OF PLANS OR STRATEGY THAT INVOLVE RISKS AND UNCERTAINTIES. MANAGEMENT WISHES TO CAUTION THE READER THAT THESE FORWARD-LOOKING STATEMENTS, INCLUDING, BUT NOT LIMITED TO, STATEMENTS REGARDING THE COMPANY AND ITS PLANS OR INTENTIONS, ESTIMATES, GOALS, COMPETITIVE TRENDS AND OTHER MATTERS THAT ARE NOT HISTORICAL FACTS ARE ONLY PREDICTIONS. NO ASSURANCES CAN BE GIVEN THAT SUCH PREDICTIONS WILL PROVE CORRECT OR THAT THE ANTICIPATED FUTURE RESULTS WILL BE ACHIEVED. ACTUAL EVENTS OR RESULTS MAY DIFFER MATERIALLY EITHER BECAUSE ONE OR MORE PREDICTIONS PROVE TO BE ERRONEOUS OR AS A RESULT OF OTHER RISKS FACING THE COMPANY. FORWARD-LOOKING STATEMENTS SHOULD BE READ IN LIGHT OF THE CAUTIONARY STATEMENTS AND IMPORTANT FACTORS DESCRIBED IN THIS FORM 10-Q, INCLUDING, BUT NOT LIMITED TO “THE FACTORS THAT MAY AFFECT FUTURE RESULTS” SHOWN AS ITEM 1A AND IN MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. THE RISKS INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH AN EARLY-STAGE COMPANY HAS LIMITED ASSETS AND OPERATIONS, THE COMPARATIVELY LIMITED FINANCIAL RESOURCES OF THE COMPANY, THE COMPANY IS INSOLVENT AND ITS TOTAL LIABILITIES EXCEED ITS TOTAL ASSETS, THE INTENSE COMPETITION THE COMPANY FACES FROM OTHER ESTABLISHED COMPETITORS, AND THE LEGAL UNCERTAINTIES THAT DIRECTLY AND INDIRECTLY IMPACT DEVELOPMENT-STAGE COMPANIES. ANY ONE OR MORE OF THESE OR OTHER RISKS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE FUTURE RESULTS INDICATED, EXPRESSED, OR IMPLIED IN SUCH FORWARD-LOOKING STATEMENTS. WE UNDERTAKE NO OBLIGATION TO UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENT TO REFLECT EVENTS, CIRCUMSTANCES, OR NEW INFORMATION AFTER THE DATE OF THIS FORM 10-Q OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED OR OTHER SUBSEQUENT EVENTS.

-12-

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

As used herein, the term “we,” “our,” “us,” and the “Company” refers to Kallo, Inc., a Nevada corporation unless otherwise noted.

This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. All funds are reflected in United States dollars unless otherwise indicated.

Any reading of this Quarterly Report on Form 10-Q should also include a reading of Item 1A, Risk Factors in our Annual Report on Form 10-K for the fiscal year ending December 31, 2020. We have no recent history of generating any revenues or positive cash flow and there can be no assurance that we will be successful in generating any revenues or, if we are successful in generating revenues, that we can sustain any such revenues at a level that will allow us to become solvent or otherwise operate with a positive cash flow at any time in the future. There is a high risk that the Company may be facing severe and prolonged financial adversity with the high likelihood that the Company’s stockholders will lose their entire investment.

We are a small company with limited financial and managerial resources and we are insolvent. There is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills and meet our operating expenses. This is because we have generated insignificant revenues from our operations during the last ten years. We have been able to remain in business as a result of investments, in debt or equity securities, by our officers and directors and by other unrelated parties. We expect to incur operating losses in the foreseeable future and our ability to continue as a going concern is dependent upon our ability to raise additional money through investments by others and achieve profitable operations. There is no assurance that we will be able to raise additional money or that additional money or that additional financing will be available to us on satisfactory terms or that we will be able to achieve profitable operations. The consolidated statements were prepared under the assumption that we will continue as a going concern, however, there can be no assurance that such financial support shall be ongoing or available on terms or conditions acceptable to the Company. This raises substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

For the last ten fiscal years, starting January 2010, our management and board of directors have raised funds through a personal and professional network of investors. This has enabled product and business development, continued operations, and generation of customer interest. In order to continue operations, management has contemplated several options to raise capital and sustain operations in the next 12 months. These options include, but are not limited to, debt and equity offers to existing shareholders, debt and equity offers to independent investment professionals and through various other financing alternatives. We currently believe that if we can secure sufficient additional capital on a timely basis, in sufficient amounts and on reasonable terms and if we are successful in securing at least one project that likely will enable us to continue operations for the next 12 months. There can be no guarantee that we will receive sufficient additional capital on a timely basis and on reasonable terms that will allow is to continue to remain in business. Currently we have not received any commitment from any third party to provide the additional capital that we believe we will require to sustain our Company as a corporate entity or otherwise allow us to meet our financial obligations.

On April 8, 2017, the Company entered into an agreement with FE Pharmacy Inc. whereby in consideration for the issuance of 475,000,000 common stock of Kallo, FE Pharmacy Inc. assumed and will pay all of the Company’s outstanding indebtedness as of April 7, 2017. Management believes that with this agreement in place, it can concentrate on bringing the potential projects as detailed below to fruition and if circumstances allow and if we can avoid further severe financial decline, any additional funding may be met through one of the three options mentioned above.

In 2017 the Government of Ghana initiated several discussions with us, to revisit how the Ministry of Defense – Military Hospital requirements, the Ministry of Health healthcare infrastructure requirements and the Ministry of Education Teaching Hospital infrastructure requirements can be met using the Kallo Integrated Delivery Model. The success of these discussions confirmed Ghana’s continued belief in the Kallo Integrated Delivery System, as the best solution for the nation’s healthcare infrastructure development, which is very encouraging for our continued business in Ghana.

-13-

Table of Contents

On June 20, 2017, our branch office was legally registered in Ghana. A valid tax identification number was issued and this number is to be used by us in all of our anticipated business that we hope to conduct within Ghana. We have incorporated four SPVs (Special Purpose Vehicles / Companies) to oversee the various projects we seek to undertake in Ghana. The SPVs are all incorporated under the laws of Ghana as private companies. Based on our internal management assessments conducted without the benefit of any independent third-party review or evaluation, we believe that our business plans involving Ghana are sound and may offer us significant business opportunities. However, we cannot assure you that we will be able to obtain sufficient financing on reasonable terms and on a timely basis that will allow us to pursue these opportunities.

We have entered into four major concession agreements with four key governmental institutions in Ghana. We have also, through our SPVs has entered into the following concession arrangements for the construction and operation of various hospital facilities in Ghana:

	Project Description	Kallo SPV
1	Tamale Military Hospital project	K-TMH Ghana Limited
2	Cape Coast Teaching Hospital project	K-UCC Cape Coast Limited
3	Sunyani Teaching Hospital project	K-UENR Sunyani Limited
4	Ho Teaching Hospital project	K-UHAS Ho Limited

These agreements are effective upon execution and the concession period will start from the date on which financial close is achieved with the Lenders and all conditions precedent are satisfied or waived. The financing has not closed yet and there is no guarantee that financial close will be achieved.

The Global need for standardized healthcare service delivery to all geographies and to all people is the fundamental business driver for the innovation of the Kallo Integrated Delivery System – “KIDS”.

This unique and comprehensive concept was developed based on first hand discovery and a detailed study of ground realities and causal analysis over 15 years. The business issues in the current healthcare systems are addressed by intricate orchestration of technologies both proprietary and off the shelf to create a standardized healthcare delivery model across the continuum of care.

A strategic market approach was defined for customers to take a well-informed decision and to work with Kallo on a national strategy for healthcare infrastructure and a standardized healthcare services delivery model across the country. This led to the development of a structured business development process and management for business success.

After many years of hard work in developing countries we now see a dynamic shift in the thought process within the developing countries to consider innovative solutions leveraging technology for strengthening and advancing their healthcare infrastructure and services delivery for all citizens alike.

On June 26, 2020, the Cabinet Secretary of the Department of Health and the Cabinet Secretary of the National Treasury and Planning of the Republic of Kenya entered into a Project Contract with Kallo Inc. and a Loan Contract with Techno-Investment Module Ltd., now with its registered office in Spain for implementing Kallo Integrated Delivery Systems (KIDS) in the Republic of Kenya to strengthen their National Healthcare Infrastructure and build a robust, sustainable healthcare ecosystem.

On November 10, 2020, the Minister of Health and the Minister of Finance of the Kingdom of Eswatini entered into a Project Contract with Kallo Inc. and a Loan Contract with Techno-Investment Module Ltd., now with its registered office in Spain for implementing Kallo Integrated Delivery Systems (KIDS) in the Republic of Kenya to strengthen their National Healthcare Infrastructure and build a robust, sustainable healthcare ecosystem.

-14-

Table of Contents

On November 30, 2020, the Minister of Health and the Minister of Finance of the Federal Democratic Republic of Ethiopia entered into a Project Contract with Kallo Inc. and a Loan Contract with Techno-Investment Module Ltd., now with its registered office in Spain for implementing Kallo Integrated Delivery Systems (KIDS) in the Republic of Kenya to strengthen their National Healthcare Infrastructure and build a robust, sustainable healthcare ecosystem. Included in the contract is Medical Tourism project with a Medical Center of Excellence.

On December 10, 2020, the Minister of Health and the Minister of Finance of the Republic of Mozambique entered into a Project Contract (Phase-1) with Kallo Inc. and a Loan Contract (Phase-1) with Techno-Investment Module Ltd., now with its registered office in Spain for implementing Kallo Integrated Delivery Systems (KIDS) in the Republic of Kenya to strengthen their National Healthcare Infrastructure and build a robust, sustainable healthcare ecosystem.

On December 11, 2020, the Minister of Health and the Minister of Finance of the State of Eritrea entered into a Project Contract with Kallo Inc. and a Loan Contract with Techno-Investment Module Ltd., now with its registered office in Spain for implementing Kallo Integrated Delivery Systems (KIDS) in the Republic of Kenya to strengthen their National Healthcare Infrastructure and build a robust, sustainable healthcare ecosystem.

Plan of Operation

The following plan of operation contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth elsewhere in this document. Because of the speculative nature of our operations and the nature of the African countries we are attempting to do business with, there is no assurance that any of the planned operations will occur.

To the extent that we are financially able and if circumstances allow, we plan to continue to develop components of Kallo Integrated Delivery System:

Kallo Integrated Delivery System (KIDS)

MobileCare^TM– a mobile trailer that opens into a state of the art clinical setup in a vehicle equipped with the latest technology in healthcare. More than just a facility, MobileCare TM can instantly connect the onboard physician with specialists for on-demand consultation via satellite through its Telehealth system. This is truly a holistic approach to delivering healthcare to the remotely located. For many rural communities, the nearest hospital, doctor or nurse may be hundreds of kilometers away. In many cases, this gap can be bridged using Telehealth technology that allows patients, nurses and doctors to talk as if they were in the same room.

RuralCare^TM– prefabricated modular healthcare units focused in rural areas where no roads infrastructure is available. They are equipped to provide primary healthcare including X-Ray, ultrasound, surgery, pharmacy and lab services. Ranging from 1,200 to 3,800 square feet, these clinics can be up and running in disaster zones or rural areas in as little as one week. Similar to the MobileCare ^TM product, RuralCare ^TM also utilizes satellite communications to access the Telehealth system.

Our overall healthcare mission is to “reach the unreached”. Based on our own internal assessments conducted by our officers and without the benefit of any independent third party evaluation, we believe that may be able to offer end-to-end solution that may include the following:

Global command center – located in the Kallo headquarters in Canada, this is the escalation point for the coordination of delivery of Telehealth and eHealth support. It consists of both the Clinical Command Center and the Administrative Command Center.

Regional command centers, Clinical and Administrative – located in the urban area hospitals and connected with satellite communications, these centers coordinate all aspects of the healthcare delivery solution with the Mobile clinics and Rural clinics including clinical services, Telehealth services, pharmacy and medical consumable coordination as well as escalations to the Global response center.

-15-

Table of Contents

Kallo University – provides education, training and development of local resources for all aspects of the healthcare delivery which includes clinical, engineering and administration.

Emergency Medical Services – provides ground and air ambulance vehicles for emergency patient transport. We have now incorporated Medical Drone Services.

Based solely on our internal management assessments conducted without the benefit of any independent third-party review or evaluation, we believe that our end-to-end delivery solution is equipped with necessary medical equipment as per regional healthcare requirements. We also install our copyrighted software and third party software as required along with a five (5) year support agreement renewable after the five (5) year initial term that includes the medical equipment, software licenses, installation implementation and training. If we are successful then we anticipate that may, if circumstances are favorable, allow us to generate an ongoing revenue stream for service, maintenance, spare-parts, and consumables. However, we can not assure you that even if we are able to achieve these goals that we can do so at levels that may allow us to achieve and sustain positive cash flow and profitability. We have incurred significant and protracted losses and we have no record of achieving and sustaining positive cash flow and profitability and we can not be certain that we will achieve either or both of these goals at any time in the future.

Business Overview

The business development model, unique to KIDS, included in-country stakeholder workshops and white-board sessions on the KIDS concept and its application in their context of healthcare infrastructure and healthcare services delivery model.

Kallo instituted the concept of conducting detailed Clinical, Engineering and Technology studies led by Kallo to establish detailed requirements for preparation of a customized proposal for the country and a phased roll out plan.

In addition, Kallo has addressed the major issue of financing such large initiatives in under developed countries by developing a network of financial institutions and Banks across the globe focused on humanitarian and healthcare projects.

-16-

Table of Contents

Go-To-Market Strategy

Our Sales Go-To-Market Strategy is segmented based on the varying needs of our customers in the following three categories:

Full solution with Kallo Integrated Delivery System (KIDS) – typically longer sales cycle and includes the end to end solution of Mobile Clinics, Rural Poly Clinics, Global and Regional response centers, Clinical and Administrative command centers, telehealth support, Kallo University training, pharmacy and medical consumable support and Emergency services with ground and air ambulance vehicles. This solution is focused on the end-to-end healthcare needs of developing countries.

Medical Tourism

COVID-19 Rapid Response Program

Kallo’s Value Proposition

●

Laying the foundational elements in building the primary care infrastructure for an entire country

●

Providing Technologies for current and future adoption of advancements in clinical services such as Telemedicine, remote maintenance and management etc.

●

Creating operational policies and procedures to set higher standards of care

●

Provide Education and training to build resource capacity within the country

●

KIDS provide a modular and flexible Point-of-Care facility to enable healthcare services from cities to the most rural areas in a given country and helps overcome inequalities in healthcare services across all geographies.

Kallo’s Key Market Differentiators

Kallo differentiates itself in our market segment by offering the most comprehensive and holistic healthcare deliver solution available to meet the needs of developing countries and countries with rural and remote populations. Kallo has invested considerable time and energy studying and understanding the healthcare needs of our target market.

Unequivocal Differentiators

Care platforms (Point-of-care facilities - Mobile Clinics, Rural clinics & Modular Hospitals) manufactured to North American and internationally accepted standards

Programs, facilities and services set-up to proactively detect and treat infectious diseases

On-going Tele-health service support, leveraging both local and international expertise

On-going education, training, & certification programs offered through Kallo University

On-going service & maintenance programs for all facilities and equipment

Leverages local skillsets and creates employment opportunities

Competitive Landscape

Healthcare landscape is the most complex industry at large. It has developed in each area of its function in an isolated fashion and hence today we have disparate functions, technologies and infrastructure. Globally healthcare industry leaders are working hard to bring a synchronized approach in patient encounter, diagnosis and treatment including preventive care. Kallo has leaped into the future with the KIDS concept and have successfully brought together technologies including global telemedicine, infrastructure and functional expertise leading the industry and have created the Kallo business ecosystem.

-17-

Table of Contents

Kallo Integrated Delivery System (KIDS) has been the key to our success in the under-developed, countries and will take a lead into developing and developed countries with the flexibility of deploying components of KIDS.

Need for additional capital

We have incurred significant and protracted operating losses since inception and have an accumulated deficit and a working capital deficit at March 31, 2020. We expect to incur additional losses as we execute our go to market strategy. This raises substantial doubt about the Company’s ability to continue as a going concern.

We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a business enterprise, including limited capital resources and possible cost overruns due to price increases in services and products.

To become profitable and competitive, we anticipate that we will have to sell our products and services in sufficient volumes and with margins that may allow us to achieve profitability. We cannot assure you or anyone that we will be successful in these efforts and that we will avoid any of the severe financial and nonfinancial consequences that commonly result when a corporation is insolvent.

There is no guaranty that we will obtain sufficient additional financing on a timely basis and on reasonable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop, or expand our operations. Any equity financing will likely result in immediate and substantial dilution of existing stockholders.

Results of operations

Revenues

We did not generate any revenues during the three months ended March 31, 2020 or 2019. However, we are pursuing what we hope may be suitable business opportunities that, based on our own internal management assessments conducted without the benefit of any independent third-party review or evaluation, may offer us commercially feasible and appropriate opportunities. However, we cannot assure you that we will be successful in any of these matters or, if we achieve any success, that it will allow to achieve and sustain positive cash flow and profitability. We are insolvent and we continue to incur losses with no assurance that we will ever generate any revenues or if we do generate any revenues that we can sustain such revenues at any level in excess of our costs.

Expenses

During the three months ended March 31, 2020 we incurred total expenses of $145,008, including $92,654 in salaries and compensation, $2,000 in professional fees, $27,746 in interest and financing costs, $18,563 in selling and marketing and $4,045 as other expenses offset by gain on foreign exchange of $306,223 whereas during the three months ended March 31, 2019 we incurred total expenses of $1,804,738, including $1,672,873 in salaries and compensation, $32,897 in professional fees. $27,442 in interest and financing costs, $64,736 in loss on foreign exchange, $1,086 in selling and marketing and $5,704 as other expenses.

The decrease in our total expenses for the three months ended March 31, 2020 from the comparative period is mainly due to a decrease in salaries and compensation of $1,580,219 due to non-cash stock-based compensation of $1,574,480, a decrease in professional fees of $30,897. There is also a positive change in foreign exchange of $370,959 due to the appreciation of the US dollar vis a vis the Canadian dollar.

The Company is operating with a minimal number of full time employees and office space until it can secure new contracts.

-18-

Table of Contents

Net Loss

During the three months ended March 31, 2020 we did not generate any revenues and incurred a net income of $161,215 compared to a net loss of $1,804,738 during the same period in 2019. The main reasons were the decrease in salaries and compensation and favorable movement in foreign exchange as discussed above. In that respect, we cannot assure you that we will be successful in reducing our losses at any time in the future and we may face significant and protracted financial losses and we cannot guarantee that we will achieve any of our business goals. We are insolvent and our Total Liabilities exceed our Total Assets and we may become more insolvent unless and until we can generate sufficient revenues and positive cash flow that may allow us to meet our financial and legal obligations to our creditors.

Liquidity and capital resources

As at March 31, 2020, the Company had no current assets and current liabilities of $6,655,001, indicating working capital deficiency of $6,655,001. As of March 31, 2020, we had no assets and our total liabilities were $6,655,001 comprised of $3,665,380 in accounts payable and accrued liabilities, convertible loans payable of $1,200,095, short term loans of $65,236 and liability for issuable shares of $1,724,290.

Cash used in operating activities amounted to $200 during the three months ended March 31, 2020, primarily as a result of the net loss adjusted for non-cash items and various changes in operating assets and liabilities.

Cash provided by financing activities amounted to $200 from proceeds from short term loans payable.

There was no cash movement in investing activities during the current three months period ended March 31, 2020.

As of March 31, 2020, our Total Liabilities exceeded our Total Assets and we were insolvent. In that respect we face all the risks and uncertainties of any insolvent corporation that could easily result in stockholders losing all or substantially all of their investment. Our common stock and our preferred stock are securities that should only be acquired by persons who can accept the HIGH RISK of such an investment and the total loss of their investment.

-19-

Table of Contents

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4.

CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We conducted an evaluation (the “Evaluation”), under the supervision and with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of the end of the period covered by this report pursuant to Rule 13a-15 of the Exchange Act. Based on this Evaluation, our CEO and CFO concluded that our Disclosure Controls were not effective as of the end of the period covered by this report due to lack of segregation of duties in financial reporting and presence of adjusting journal entries during the audit as well as insufficient controls over the financial close process and preparation of the financial statements.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

On October 24, 2016, a consultant obtained a judgement ordering Kallo to pay Canadian $34,924 for unpaid fees. The full amount has been accrued for in the financial statements of Kallo.

While we believe that we may be successful in resolving these claims, we cannot assure that the outcome will not have a material adverse effect upon us.

-20-

Table of Contents

ITEM 1A.

RISK FACTORS.

Our Common Stock is subject to a number of substantial risks, including those described below. No attempt has been made to rank these risks in the order of their likelihood or potential harm. In addition to those general risks enumerated elsewhere in the document, any purchaser of the Company’s common stock should also consider the following risk factors:

Risks Related to the Ownership of the Company’s Stock

1. No Revenues from Operations & Continuing Losses; Risk of Loss & Insolvency. During the past two fiscal years we have not generated and revenues and there can be no assurances that we will be successful in generating revenues in the future. In that respect we face all of the risks inherent in an early-stage business. We have incurred losses and there can be no assurance that we will ever achieve profitability and positive cash flow. While we believe that our business strategies are sound, there can be no assurance that our business will generate profits and positive cash flow or if we generate profits and positive cash flow, that it can be sustained. Investors should be aware that they may lose all or substantially all of their investment. We are also insolvent since our Total Liabilities exceed our Total Assets.

2. Limited Corporate Officers & Employees. We have only three corporate officers, one of which is part-time and an aggregate of four employees, including our three officers. As a result, we may not be able to evaluate ever-changing market, technology and competitive trends effectively and we are likely to incur significant additional losses thereby.

3. Auditor’s Opinion: Going Concern & Insolvency. Our independent auditors have expressed substantial doubt about the Company’s ability to continue as a going concern since: (a) our Total Current Liabilities exceed our Total Current Assets; (b) our Total Liabilities exceed our Total Assets; and (c) we are an early-stage company and there exists only a limited history of operations. Since our Total Liabilities exceed our Total Assets, we are insolvent and anyone who acquires our Common Stock should be prepared to lose their entire investment.

4. Limited Financial Resources; Need for Additional Financing. Our financial resources are minimal and we are insolvent. We need to obtain additional financing from the sale of our Common Stock, Debt, or some combination thereof in order to undertake further business plans. Our ability to operate as a going concern is contingent upon our receipt of additional financing through private placements or by loans. We anticipate that we will require significant additional funds in the future if we are successful in marketing our products and services. There can be no assurance that if additional funds are required they will be available, or, if available, that they can be obtained on terms satisfactory to our Board of Directors. In the event the Company elects to issue stock to raise additional capital, any rights or privileges attached to such stock may either (i) dilute the percentage of ownership of the already issued common shares or (ii) dilute the value of such shares; or (iii) both. No rights or privileges have been assigned to the stock and any such rights and privileges will be at the total discretion of the Board of Directors of the Company. There can be no guarantee that we will be able to obtain additional financing, or if we are successful, that we will be able to do so on terms that are reasonable in light of current market conditions. Further, we have not received any commitment from any person to provide any additional financing and we cannot assure that any such commitment is forthcoming.

5. Limited and Sporadic Trading Market for Common Stock. Our Common Stock trades on the OTC Market on a limited and sporadic basis and there can be no assurance that a liquid trading market for our Common Stock will develop and, if it does develop, that it can be sustained.

6. Lack of Revenues And Development Stage Company. We have no history of generating Sales Revenues and we cannot assure that we will generate any Sales Revenues in the future or, if we do, that we can achieve Sales Revenues at a level that will allow us to also achieve and maintain profitability and positive cash flow. We face all of the risks inherent in a new business. There is no information at this time upon which to base an assumption that our plans will either materialize or prove successful. Our present business plans and strategies have been developed by our corporate officers and they have been evaluated by any independent third party. plans have not been determined. There can be no assurance that any of our business plans and strategies will generate sales revenues that will result in any profits or positive cash flow. Investors should be aware that they may lose all or substantially all of their investment.

7. Lack of Dividends & No Likelihood of Dividends. We have not paid dividends and do not contemplate paying dividends in the foreseeable future.

-21-

Table of Contents

8. Competition. We are an insignificant participant among firms which offer health care products and services. There are many well-established health care product and service companies which have significantly greater financial and managerial resources, technical expertise and experience than the Company. In view of our limited financial and managerial resources, we will likely be at a significant competitive disadvantage vis-a-vis our competitors.

9. No Ability to Control & Matter of Voting Rights Held by our President. Any person who acquires our Common Stock will have no real ability to influence or control the Company or otherwise have any ability to elect any person to our Board of Directors. Our officers, directors, and certain other persons currently control the Company and there is no likelihood that any person who acquires our Common Stock will have any real ability to influence or control the Company in any meaningful way. Further and at present, our President, John Cecil, is the owner and holder of 5,000,000 shares of our Series B Preferred Stock with each share having one thousand (1,000) votes per share with the right to vote with our Common Stockholders at any meeting of or action taken by the holders of our Common Stock. As a result, Mr. Cecil has the clear ability to control the Company via the exercise of his voting rights provided by the Series B Preferred Stock and all of the holders of our Common Stock effectively have no real ability to exercise any influence upon the affairs of the Company. In addition, Mr. Cecil is the owner and holder of 70,000,000 shares of the Company’s Series A Preferred Stock with each Series A Preferred share having one hundred (100) votes per share. As a result of the foregoing, any holder or group of holders of our Common Stock will have no reasonable ability to influence or control the Company’s policies, affairs, or strategies.

10. Negative Equity. Our Total Liabilities exceed our Total Assets. As a result, we are insolvent and we cannot assure you that we will be able to become solvent at any time in the future.

11. Possible Rule 144 Stock Sales. Many of our shares of our outstanding Common Stock are “restricted securities” and may be sold only in compliance with Rule 144 adopted under the Securities Act of 1933, as amended or other applicable exemptions from registration. Any person who acquires our common stock in any private placement should carefully review Rule 144 since any potential public resale may be limited and current broker-dealer and clearing firm requirements may make any re-sale of our common stock difficult at best.

12. Absence of Underwriter Commitment. Based on our current plans, we anticipate that we will likely need to raise significant additional capital to meet our current and anticipated financial needs, we have not received any commitment from any registered broker-dealer or underwriter to assist us in raising needed capital. As a result, we face a clear risk that we will not have sufficient cash resources to meet our current financial obligations and otherwise implement our business plans. In that event, we may not be able to implement our plans and we will not be able to achieve profitability and positive cash flow or, if we do, that we can sustain either or both of them for any period of time.

13. Risks of Low Priced Stocks. Currently, our common stock is not trading in any market and there is no certain prospect that the Company’s common stock will regain any trading in any organized market. In the past, the Company’s common stock had only limited and sporadic trading in the so-called “pink sheets,” and before that, on the “Electronic Bulletin Board.” As a result and due to the absence of a market, a shareholder may find it more difficult to dispose of, or to obtain accurate quotations as to the price of, the Company’s securities. In the absence of a security being quoted on NASDAQ, or the Company having $2,000,000 in net tangible assets, trading in the Common Stock is covered by Rule 3a51-1 promulgated under the Securities Exchange Act of 1934 for non-NASDAQ and non-exchange listed securities. Under such rule, broker/dealers who recommend such securities to persons other than established customers and accredited investors (generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or an annual income exceeding $200,000 or $300,000 jointly with their spouse) must make a special written suitability determination for the purchaser and receive the purchaser’s written agreement to a transaction prior to sale.

In general, securities are also exempt from this rule if the market price is at least $5.00 per share, or for warrants, if the warrants have an exercise price of at least $5.00 per share. The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure related to the market for penny stocks and for trades in any stock defined as a penny stock. The Commission has recently adopted regulations under such Act which define a penny stock to be any NASDAQ or non-NASDAQ equity security that has a market price or exercise price of less than $5.00 per share and allow for the enforcement against violators of the proposed rules.

In addition, unless exempt, the rules require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule prepared by the Commission explaining important concepts involving the penny stock market, the nature of such market, terms used in such market, the broker/dealer’s duties to the customer, a toll-free telephone number for inquiries about the broker/dealer’s disciplinary history, and the customer’s rights and remedies in case of fraud or abuse in the sale.

Disclosure also must be made about commissions payable to both the broker/dealer and the registered representative, current quotations for the securities, and if the broker/dealer is the sole market-maker, the broker/dealer must disclose this fact and its control over the market.

-22-

Table of Contents

Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. While many NASDAQ stocks are covered by the proposed definition of penny stock, transactions in NASDAQ stock are exempt from all but the sole market-maker provision for (i) issuers who have $2,000,000 in tangible assets ($5,000,000 if the issuer has not been in continuous operation for three years), (ii) transactions in which the customer is an institutional accredited investor and (iii) transactions that are not recommended by the broker/dealer. In addition, transactions in a NASDAQ security directly with the NASDAQ market-maker for such securities, are subject only to the sole market-maker disclosure, and the disclosure with regard to commissions to be paid to the broker/dealer and the registered representatives.

Finally, all NASDAQ securities are exempt if NASDAQ raised its requirements for continued listing so that any issuer with less then $2,000,000 in net tangible assets or stockholder’s equity would be subject to delisting. These criteria are more stringent than the proposed increased in NASDAQ’s maintenance requirements.

Our securities are subject to the above rules on penny stocks and the market liquidity for our securities could be severely affected by limiting the ability of broker/dealers to sell our securities.

-23-

Table of Contents

ITEM 6.

EXHIBITS.

The following documents are included herein:

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

2.1	Articles of Merger	8-K	1/21/11	2.1

3.1	Articles of Incorporation	SB-2	3/05/07	3.1

3.2	Bylaws	SB-2	3/05/07	3.2

3.3	Amended Articles of Incorporation (11/23/2015)	8-K	12/02/15	3.1

4.1	Specimen Stock Certificate	SB-2	3/05/07	4.1

10.1	Agreement with Rophe Medical Technologies Inc. dated December 11, 2009	10-K	3/31/10	10.2

10.2	Amended Agreement with Rophe Medical Technologies Inc. dated December 18, 2009	10-K	3/31/10	10.3

10.3	Amended Agreement with Rophe Medical Technologies Inc. dated March 16, 2010	10-K	3/31/10	10.4

10.4	Investment Agreement with Kodiak Capital Group, LLC dated October 20, 2014	S-1	10/30/14	10.6

10.5	Amended Agreement with Jarr Capital Corp.	8-K	2/22/11	10.1

10.6	Termination of Employment Agreement with John Cecil	8-K	2/22/11	10.2

10.7	Termination of Employment Agreement with Samuel Baker	8-K	2/22/11	10.4

10.8	Services Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/11	10.1

10.9	Equipment Lease Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/11	10.2

10.10	Agreement with Mansfield Communications Inc.	10-K	5/18/11	10.3

10.11	Agreement with Watt International Inc.	10-K	5/18/11	10.4

10.12	Pilot EMR Agreement with Nexus Health Management Inc.	10-K	5/18/11	10.5

10.13	2011 Non-Qualified Stock Option Plan	S-8	6/27/11	10.1

10.14	Multimedia Contractual Agreement with David Miller	8-K	10/28/11	10.1

-24-

Table of Contents

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

10.15	Strategic Alliance Agreement with Petro Data Management Services Limited and Gateway Global Fabrication Ltd.	8-K	11/02/11	10.1

10.16	Independent Contractor Agreement with Savers Drug Mart	8-K	1/26/12	10.1

10.17	2012 Non-Qualified Stock Option Plan	S-8	9/06/12	10.1

10.18	Memorandum of Offering with Ministry of Health of Republic of Ghana	S-1/A-3	6/26/13	10.32

10.19	Addendum to Investment Agreement with Kodiak	S-1/A-4	7/31/13	10.33

10.20	Second Addendum to Investment Agreement with Kodiak	S-1	8/25/14	10.34

10.21	Email from Kodiak	S-1/A-1	9/24/14	10.35

10.22	Email from Kodiak	S-1/A-1	9/24/14	10.36

14.1	Code of Ethics	S-1	8/25/14	14.2

16.1	Letter from Collins Barrow Toronto LLP	8-K/A-1	2/15/12	16.3

16.2	Letter from Schwartz Levitsky Feldman LLP	8-K/A-3	8/13/14	16.1

21.1	List of Subsidiary Companies	10-K	3/31/10	21.1

31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X

99.1	Audit Committee Charter	10-K	4/15/08	99.1

99.2	Disclosure Committee Charter	10-K	4/15/08	99.2

99.3	FCPA Code	S-1	8/25/14	99.3

99.4	Letter from Ministry of Health	8-K	6/08/15	99.2

99.5	Letter from Minister of Health and Public Hygiene	8-K	6/24/15	99.2

-25-

Table of Contents

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

101.INS	XBRL Instance Document				X

101.SCH	XBRL Taxonomy Extension – Schema				X

101.CAL	XBRL Taxonomy Extension – Calculations				X

101.DEF	XBRL Taxonomy Extension – Definitions				X

101.LAB	XBRL Taxonomy Extension – Labels				X

101.PRE	XBRL Taxonomy Extension – Presentation				X

-26-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 3^rd day of March, 2021.

	KALLO INC.
	(The “Registrant”)

	BY:	JOHN CECIL
		John Cecil
		President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, and a Chairman of the Board of Directors

-27-

Table of Contents

EXHIBIT INDEX

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

2.1	Articles of Merger	8-K	1/21/11	2.1

3.1	Articles of Incorporation	SB-2	3/05/07	3.1

3.2	Bylaws	SB-2	3/05/07	3.2

3.3	Amended Articles of Incorporation (11/23/2015)	8-K	12/02/15	3.1

4.1	Specimen Stock Certificate	SB-2	3/05/07	4.1

10.1	Agreement with Rophe Medical Technologies Inc. dated December 11, 2009	10-K	3/31/10	10.2

10.2	Amended Agreement with Rophe Medical Technologies Inc. dated December 18, 2009	10-K	3/31/10	10.3

10.3	Amended Agreement with Rophe Medical Technologies Inc. dated March 16, 2010	10-K	3/31/10	10.4

10.4	Investment Agreement with Kodiak Capital Group, LLC dated October 20, 2014	S-1	10/30/14	10.6

10.5	Amended Agreement with Jarr Capital Corp.	8-K	2/22/11	10.1

10.6	Termination of Employment Agreement with John Cecil	8-K	2/22/11	10.2

10.7	Termination of Employment Agreement with Samuel Baker	8-K	2/22/11	10.4

10.8	Services Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/11	10.1

10.9	Equipment Lease Agreement with Buchanan Associates Computer Consulting Ltd.	10-K	5/18/11	10.2

10.10	Agreement with Mansfield Communications Inc.	10-K	5/18/11	10.3

10.11	Agreement with Watt International Inc.	10-K	5/18/11	10.4

10.12	Pilot EMR Agreement with Nexus Health Management Inc.	10-K	5/18/11	10.5

10.13	2011 Non-Qualified Stock Option Plan	S-8	6/27/11	10.1

10.14	Multimedia Contractual Agreement with David Miller	8-K	10/28/11	10.1

-28-

Table of Contents

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

10.15	Strategic Alliance Agreement with Petro Data Management Services Limited and Gateway Global Fabrication Ltd.	8-K	11/02/11	10.1

10.16	Independent Contractor Agreement with Savers Drug Mart	8-K	1/26/12	10.1

10.17	2012 Non-Qualified Stock Option Plan	S-8	9/06/12	10.1

10.18	Memorandum of Offering with Ministry of Health of Republic of Ghana	S-1/A-3	6/26/13	10.32

10.19	Addendum to Investment Agreement with Kodiak	S-1/A-4	7/31/13	10.33

10.20	Second Addendum to Investment Agreement with Kodiak	S-1	8/25/14	10.34

10.21	Email from Kodiak	S-1/A-1	9/24/14	10.35

10.22	Email from Kodiak	S-1/A-1	9/24/14	10.36

14.1	Code of Ethics	S-1	8/25/14	14.2

16.1	Letter from Collins Barrow Toronto LLP	8-K/A-1	2/15/12	16.3

16.2	Letter from Schwartz Levitsky Feldman LLP	8-K/A-3	8/13/14	16.1

21.1	List of Subsidiary Companies	10-K	3/31/10	21.1

31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X

99.1	Audit Committee Charter	10-K	4/15/08	99.1

99.2	Disclosure Committee Charter	10-K	4/15/08	99.2

99.3	FCPA Code	S-1	8/25/14	99.3

99.4	Letter from Ministry of Health	8-K	6/08/15	99.2

99.5	Letter from Minister of Health and Public Hygiene	8-K	6/24/15	99.2

-29-

Table of Contents

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith

101.INS	XBRL Instance Document				X

101.SCH	XBRL Taxonomy Extension – Schema				X

101.CAL	XBRL Taxonomy Extension – Calculations				X

101.DEF	XBRL Taxonomy Extension – Definitions				X

101.LAB	XBRL Taxonomy Extension – Labels				X

101.PRE	XBRL Taxonomy Extension – Presentation				X

-30-

EX-31.1 2 kalo-20200331_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, John Cecil, certify that:

1.	I have reviewed this Form 10-Q for the period ending March 31, 2020 of Kallo Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 3, 2021		*JOHN CECIL*
		John Cecil
		Principal Executive Officer and Principal Financial Officer

EX-32.1 3 kalo-20200331_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kallo Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date here of (the “report”), I, John Cecil, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 3^rd day of March, 2021.

	*JOHN CECIL*
	John Cecil
	Chief Executive Officer and Chief Financial Officer

EX-101.CAL 4 kalo-20200331_cal.xml XBRL CALCULATION FILE EX-101.INS 5 kalo-20200331.xml XBRL INSTANCE FILE 0001389034 2020-01-01 2020-03-31 0001389034 2019-12-31 0001389034 2020-03-31 0001389034 KALO:ConvertibleDebtSecurities1Member 2020-03-31 0001389034 KALO:ConvertibleDebtSecurities1Member 2019-12-31 0001389034 KALO:ConvertibleDebtSecurities2Member 2020-03-31 0001389034 KALO:ConvertibleDebtSecurities2Member 2019-12-31 0001389034 2019-01-01 2019-03-31 0001389034 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001389034 us-gaap:PreferredStockMember 2020-03-31 0001389034 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001389034 us-gaap:CommonStockMember 2020-03-31 0001389034 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001389034 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001389034 KALO:AssignmentOfLiabilitiesMember 2020-01-01 2020-03-31 0001389034 KALO:AssignmentOfLiabilitiesMember 2020-03-31 0001389034 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001389034 us-gaap:RetainedEarningsMember 2020-03-31 0001389034 KALO:ShortTermDebt1Member 2020-03-31 0001389034 KALO:ShortTermDebt1Member 2019-12-31 0001389034 KALO:ShortTermDebt2Member 2020-03-31 0001389034 KALO:ShortTermDebt2Member 2019-12-31 0001389034 2021-01-31 0001389034 2019-01-01 2019-12-31 0001389034 us-gaap:PreferredStockMember 2019-12-31 0001389034 us-gaap:CommonStockMember 2019-12-31 0001389034 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001389034 KALO:AssignmentOfLiabilitiesMember 2019-12-31 0001389034 us-gaap:RetainedEarningsMember 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Kallo Inc. 0001389034 2020-03-31 false --12-31 Yes Non-accelerated Filer Q1 2020

66521

65236

15347

16431

49889

49758

0.00001

100000000

95000000

0.00001

1150000000

1147698199

1172349

1200095

271412

265217

928683

907132

3860499

3665380

265217

271412

907132

928683

6823659

6655001

6823659

6655001

950

11478

41920116

-3462554 -3455111

-45293649

-45132434

-6823659

-6655001

950

11478

41920116

-3455111

-45132434

950

11478

41920116

-3462554

-45293649

false true 1147698199

161215

-1804738

161215

306223

-64736

27746

27442

-117262

-1712560

18563

1086

98699

1711474

-0.00

1147698199

200

26343

200

26343

-200

-26343

121070

111489

310231

-64984

27746

27442

1574480

true 1724290 1724290

1373700

95000000

1147698199

95000000

1147698199

7443

57000000

NOTE 1 – BUSINESS AND GOING CONCERN   Organization   Kallo Inc. (“Kallo” or the “Company”) develops customized health care solutions designed to improve or enhance the delivery of care in the countries and regions we serve.   Going Concern   The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The amounts of assets and liabilities in the consolidated financial statements do not purport to represent realizable or settlement values. The Company has incurred operating losses since inception and has an accumulated deficit and a working capital deficit at March 31, 2020. The Company is expected to incur additional losses as it executes its go to market strategy. This raises substantial doubt about the Company’s ability to continue as a going concern.   The Company has met its historical working capital requirements from the sale of common shares and short term loans. In order to not burden the Company, the officer/stockholder has agreed to provide funding to the Company to pay its annual audit fees, filing costs and legal fees as long as the board of directors deems it necessary. However, there can be no assurance that such financial support shall be ongoing or available on terms or conditions acceptable to the Company. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS   Basis of Presentation   The accompanying unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These unaudited consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes, which are included as part of the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.   Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year ended December 31, 2019 as reported in the 10-K have been omitted. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited consolidated financial statements.   Recently Adopted Accounting Pronouncements   In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires the use of a new current expected credit loss (“CECL”) model in estimating allowances for doubtful accounts with respect to accounts receivable. Receivables from revenue transactions, or trade receivables, are recognized when the corresponding revenue is recognized under ASC Topic 606, Revenue from Contracts with Customers. The CECL model requires that the Company estimate its lifetime expected credit loss with respect to these receivables and record allowances that when deducted from the balance of the receivables, represent the estimated net amounts expected to be collected. Given the generally short term nature of trade receivables, we do not apply a discounted cash flow methodology. However, the Company considers whether historical loss rates are consistent with expectations of forward-looking estimates for our trade receivables. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures.   Recently Issued Accounting Pronouncements   On December 18, 2019 the FASB issued the ASU 2019-12 “Income taxes (Topic 740)—Simplifying the accounting for income taxes”. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is assessing the effects that the adoption of this accounting pronouncement may have on its financial statements.

NOTE 3 – COMMON STOCK   During the three months ended March 31, 2020, there were no movements in share capital issued and outstanding.   On April 8, 2017, the Company entered into an agreement with FE Pharmacy Inc., a company controlled by a shareholder of Kallo, and a related party, whereby in consideration for the issuance of 475,000,000 common stock of Kallo, FE Pharmacy Inc. assumed and will pay all of the Company’s outstanding indebtedness as at April 7, 2017. The 475,000,000 shares issuable to FE Pharmacy Inc. has been valued at the book value of the total liabilities assigned to FE Pharmacy Inc. of $4,135,037. The assignment of the liabilities to FE Pharmacy Inc. has been recorded as a receivable in the equity section of the consolidated balance sheet and will be reduced as the liabilities are settled by FE Pharmacy Inc. During the three months ended March 31, 2020, the assignment of liabilities amount has been reduced by $7,443 cash settlement of accounts payable.

NOTE 4 – RELATED PARTY TRANSACTIONS   During the year ended December 31, 2019, the Board of Directors approved the issuance of 57,000,000 shares to directors and shareholders of the Company for par value of $570, resulting in as stock-based compensation valued at $1,373,130. These shares will be issued after the Company is able to increase its authorized number of common shares.   During the year ended December 31, 2019, the Company designated 5,000,000 of is preferred stock as Series B preferred stock, each of which has 1,000 votes and are not convertible. The Company, will not, without the approval or express written consent of the all the holders of the Series B preferred stock (i) establish, create, authorize or approve the issuance of any series or class of preferred stock (ii) change any of the rights, privileges or preferences of the Series B preferred stock or (iii) redeem the Series B preferred stock..   During the year ended December 31, 2019, the Board of Directors approved the issuance of 5,000,000 Series B preferred shares to a director as compensation for services rendered and their fair value were deemed to be $201,350 based on the voting rights of the preferred shares relative to the fair value of the Company at the date of the approved issuance. These shares will be issued after the Company becomes current on all its filings requirements.   Included in liability for issuable shares is 3,731,005 common shares valued at $149,240 and approved for issuance to a family of the controlling shareholder of FE Pharmacy Inc as compensation during 2018 which will be issued after the Company is able to increase its authorized number of common shares. The transfer agent has erroneously issued these shares in spite of the Company’s instructions to wait for the increase in authorized number of common shares.   Included in accounts payable and accrued liabilities is an amount of $1,310,980 (December 31, 2019 - $1,332,488) due to directors of the Company as of March 31, 2020.   Included in convertible loans payable to related parties is an amount of $928,683 (December 31, 2019 - $907,132), including accrued interest, owing to a director and a shareholder of the Company as of March 31, 2020.   Included in short term loans payable is an amount of $49,889 (December 31, 2019 - $49,758) due to the controlling shareholder of FE Pharmacy Inc. and a related party as at March 31, 2020.

NOTE 5 – CONVERTIBLE LOANS PAYABLE    <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; white-space: nowrap"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> March 31, 2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold; white-space: nowrap">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left">Convertible promissory notes bearing interest at 15% per annum – third parties</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">271,412</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">265,217</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible promissory notes bearing interest at 15% per annum – related parties</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">928,683</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">907,132</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">1,200,095</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">1,172,349</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td></tr> </table>   The Convertible loans payable bear 15% interest per annum and are convertible at a fixed price at any time during their 1 year term. The Company has the option to pay the note at any time. The Company analyzed the conversion option for derivative accounting consideration under ASC Topic 815-40, Derivatives and Hedging – Contract in Entity’s Own Stock and concluded that the embedded conversion was a derivative but the fair value of the feature was zero. The total outstanding notes is $1,200,095, including accrued interest, of which $928,683 is to from related parties. Interest of $27,746 on the convertible loans payable are included in net finance charge for the three months ended March 31, 2020 included in the consolidated statement of operations. All of the above convertible loans payable were in default as of March 31, 2020.

NOTE 6 – SHORT TERM LOANS PAYABLE   <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left">Non-interest bearing short term funding from third party</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">15,347</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">16,763</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1.5pt">Non-interest bearing short term funding from related party</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,889</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,758</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">65,236</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">66,521</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td></tr> </table>   As of March 31, 2020, the balance of $65,236 represented short term funding provided by a third party and a related party which are non-interest bearing, unsecured and have no fixed repayment date. The loan from third party in Canadian dollars is $21,772 which is subject to revaluation at the end of each quarter.

NOTE 7 – COMMITMENTS AND CONTINGENCIES   Contingencies   On April 21, 2017, an ex-employee of Kallo obtained a judgement ordering Kallo to pay Canadian $ 135,959 for unpaid wages and expenses relating to services performed in 2016. The full amount has been accrued for in the financial statements of Kallo.   On October 24, 2016, a consultant obtained a judgement ordering Kallo to pay Canadian $34,924 for unpaid fees. The full amount has been accrued for in the financial statements of Kallo.   On October 6, 2017, Thornley Fallis Communications Inc. (“Thornley”) commenced a third party claim against Kallo concerning monies that Kallo allegedly owed to Thornley for redesign of a website and public relation services. Thornley is seeking damages in the amount of Canadian $169,345 plus interest on the amounts outstanding and indemnification of the costs of the action. An amount of Canadian $134,960 has been accrued for in the financial statements of Kallo.   There is also a claim by Commercial Credit Adjusters on behalf of Northwest Company for payment of Canadian $34,000. An amount of Canadian $24,016 has been accrued for in the financial statements of Kallo. Negotiations are in process for the settlement of this debt for a lump sum.   Canada Revenue Agency has assessed the Company for unpaid Canadian $77,664 as at March 31, 2020 representing unremitted employee source deductions and related penalties and interest, the full amount of which has been accrued in the financial statements of Kallo.   Responsibility for payments of the above claims has been assumed by FE Pharmacy Inc. under the terms of the agreement mentioned in Note 3.

NOTE 8 – SUBSEQUENT EVENTS   On December 11, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the State of Eritrea (the “Ministry”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, the Ministry is seeking to borrow the sum of 521,437,477 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 521,437,477 Euros in four equal instalments. After receiving its share of the instalments payment, Kallo Inc. will deliver 25,000,000 Euros of each payment to the Ministry’s National Food Security Program.   On December 10, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the Republic of Mozambique (“Mozambique”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, Mozambique is seeking to borrow the sum of 1,305,256,575 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 1,305,256,575 Euros in four equal instalments. After receiving its share of the instalments payment, Kallo Inc. will then deliver 125,000,000 Euros of each payment to the Ministry’s National Food Security Program.   On November 30, 2020, the Company finalized with the Ministry of Health and the Ministry of Finance of the Federal Democratic Republic of Ethiopia (the “Borrower”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, the Borrower is seeking to borrow the sum of 2,459,817,336 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 2,459,817,336 Euros in four equal instalments to the Borrower, of which 1,860,437,075 Euros is to be used in connection with the National Healthcare Infrastructure program. After receiving its share of the instalments payment, Kallo Inc. will then deliver 125,000,000 Euros of each instalment payment received to the Borrower’s National Food Security Program.   On November 10, 2020, the Company finalized contracts with the Ministry of Health and the Ministry of Finance of the Kingdom of Eswatini (“Eswatini”) and Techno-Investment Module Limited (“TIM”) for National Healthcare Projects and Loan Agreement/Contract. Under the terms of the Agreement, Eswatini is seeking to borrow the sum of 549,978,787 Euros from TIM and the funds are to be used primarily to fund certain healthcare projects to be undertaken by Kallo Inc. TIM is to provide 549,978,787 Euros in four equal instalments to Kallo Inc and the Company will deliver 75,000,000 Euros of each payment to Eswatini’s National Food Security Program.   On June 26, 2020, the Company finalized contracts with the Republic of Kenya (“Kenya”) and Techno-Investment Module Limited (“TIM”) for a Project Contract and a Finance Contract. Under the terms of the Agreement, Kenya is seeking to borrow the sum of 1,068,932,543 Euros from TIM and the funds are to be used primarily to build phase one of a planned National Healthcare Infrastructure in the Republic of Kenya to be undertaken by Kallo Inc. In accordance with the Finance Contract, Kallo Inc. may receive up to four payments of 40,261,253 Euros in consideration for the goods and services that the Company is to provide under the Project Contract.

Basis of Presentation   The accompanying unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These unaudited consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes, which are included as part of the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.   Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year ended December 31, 2019 as reported in the 10-K have been omitted. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited consolidated financial statements.

Recently Adopted Accounting Pronouncements   In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires the use of a new current expected credit loss (“CECL”) model in estimating allowances for doubtful accounts with respect to accounts receivable. Receivables from revenue transactions, or trade receivables, are recognized when the corresponding revenue is recognized under ASC Topic 606, Revenue from Contracts with Customers. The CECL model requires that the Company estimate its lifetime expected credit loss with respect to these receivables and record allowances that when deducted from the balance of the receivables, represent the estimated net amounts expected to be collected. Given the generally short term nature of trade receivables, we do not apply a discounted cash flow methodology. However, the Company considers whether historical loss rates are consistent with expectations of forward-looking estimates for our trade receivables. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures.   Recently Issued Accounting Pronouncements   On December 18, 2019 the FASB issued the ASU 2019-12 “Income taxes (Topic 740)—Simplifying the accounting for income taxes”. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is assessing the effects that the adoption of this accounting pronouncement may have on its financial statements.

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; white-space: nowrap"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> March 31, 2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold; white-space: nowrap">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left">Convertible promissory notes bearing interest at 15% per annum – third parties</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">271,412</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">265,217</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible promissory notes bearing interest at 15% per annum – related parties</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">928,683</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">907,132</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">1,200,095</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">1,172,349</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; white-space: nowrap"> December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td> <td> </td> <td colspan="3" style="text-align: center; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 66%; text-align: left">Non-interest bearing short term funding from third party</td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">15,347</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">16,763</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1.5pt">Non-interest bearing short term funding from related party</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,889</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,758</td> <td style="text-align: left; padding-bottom: 1.5pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">65,236</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4pt double; text-align: left">$</td> <td style="border-bottom: black 4pt double; text-align: right">66,521</td> <td style="text-align: left; padding-bottom: 4pt; white-space: nowrap"> </td></tr> </table>

10-Q 98-0542529 NV 255 Duncan Mill Road, Suite 504, ON Toronto CA M3B 3H9 416 246-9997 Yes 7443 56415

EX-101.SCH 6 kalo-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficiency Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BUSINESS AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ACCOUNTING POLICIES AND OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CONVERTIBLE LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SHORT TERM LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - ACCOUNTING POLICIES AND OPERATIONS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - CONVERTIBLE LOANS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SHORT TERM LOANS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - CONVERTIBLE LOANS PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - CONVERTIBLE LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SHORT TERM LOANS PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SHORT TERM LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 7 kalo-20200331_pre.xml XBRL PRESENTATION FILE EX-101.LAB 8 kalo-20200331_lab.xml XBRL LABEL FILE Debt Instrument [Axis] Convertible promissory notes bearing interest at 15% per annum - third party Convertible promissory notes bearing interest at 15% per annum - related parties Equity Components [Axis] Preferred Stock Common Stock Additional Paid-In Capital Assignment Of Liabilities Deficit Accumulated During the Development Stage Non-interest bearing short term funding from third parties Non-interest bearing short term funding from related parties Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets: Prepaid expenses Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIENCY Liabilities Current Liabilities: Accounts payable and accrued liabilities Convertible loans payable - third parties Short term loans payable Convertible loans payable - related parties Liability for issuable shares Total Current Liabilities TOTAL LIABILITIES Commitments and Contingencies Stockholders' Deficiency Preferred stock, $0.00001 par value, 100,000,000 shares authorized, 95,000,000 Series A preferred shares issued and outstanding Common stock, $0.00001 par value, 1,150,000,000 shares authorized, 1,147,698,199 and 1,147,698,199 shares issued and outstanding, respectively. Additional paid-in capital Assignment of liabilities Accumulated deficit Total Stockholders' Deficiency TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Preferred stock, par value Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, authorized Common stock, issued Common Stock, outstanding Income Statement [Abstract] Operating Expenses General and administration Selling and marketing Operating loss Interest and financing costs Foreign exchange (loss) gain Net Income (Loss) Basic and diluted net loss per share Weighted average shares used in calculating basic and diluted net loss per share Statement [Table] Statement [Line Items] Beginning balance Beginning balance, Shares Cash settlement of liabilities Net Loss Ending balance Ending balance, Shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustment to reconcile net loss to cash used in operating activities: Stock based compensation Interest and penalties Unrealized foreign exchange loss (gain) Changes in operating assets and liabilities: Increase (decrease) in accounts payable and accrued liabilities NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from short term loans payable NET CASH PROVIDED BY FINANCING ACTIVITIES Effect of exchange rate changes on cash NET (DECREASE) INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION Income tax paid Interest paid SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Settlement of accounts payable by FE Pharmacy, Inc. Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS AND GOING CONCERN Accounting Policies [Abstract] ACCOUNTING POLICIES AND OPERATIONS Stockholders' Equity Note [Abstract] COMMON STOCK Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] CONVERTIBLE LOANS PAYABLE Short-term Debt, Other Disclosures [Abstract] SHORT TERM LOANS PAYABLE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events SUBSEQUENT EVENTS Accounting Policies And Operations Basis of Presentation Recently Adopted Accounting Pronouncements Summary of convertible loans payable Summary of short term loans payable Related Party Transactions Shares issued to directors and employees Shares issued to directors and employees, Shares Convertible loans payable Interest and Financing Cost Assignment of Liabilities Member Convertibel Debt Securities [Member] Convertibel Debt Securities [Member] Settlement of Accounts Payable Liability For Issuable Shares Assignment of Liabilities Member Convertible Loans Payable TextBlock Convertible Loans Payable Table TextBlock Short Term Debt [Member] Short Term Debt [Member] Assets, Current Assets Liabilities, Current Liabilities [Default Label] Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Shares, Outstanding Foreign Currency Transaction Gain (Loss), Unrealized Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash and Cash Equivalents, at Carrying Value EX-101.DEF 9 kalo-20200331_def.xml XBRL DEFINITION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2020	Jan. 31, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	98-0542529
Entity Registrant Name	Kallo Inc.
Entity Central Index Key	0001389034
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	255 Duncan Mill Road,
Entity Address, Address Line Two	Suite 504,
Entity Address, Address Line Three	Toronto
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M3B 3H9
City Area Code	416
Local Phone Number	246-9997
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		1,147,698,199

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Prepaid expenses
Total Current Assets
TOTAL ASSETS	0	0
Current Liabilities:
Accounts payable and accrued liabilities	3,665,380	3,860,499
Convertible loans payable - third parties	271,412	265,217
Short term loans payable	65,236	66,521
Convertible loans payable - related parties	928,683	907,132
Liability for issuable shares	1,724,290	1,724,290
Total Current Liabilities	6,655,001	6,823,659
TOTAL LIABILITIES	6,655,001	6,823,659
Commitments and Contingencies
Stockholders' Deficiency
Preferred stock, $0.00001 par value, 100,000,000 shares authorized, 95,000,000 Series A preferred shares issued and outstanding	950	950
Common stock, $0.00001 par value, 1,150,000,000 shares authorized, 1,147,698,199 and 1,147,698,199 shares issued and outstanding, respectively.	11,478	11,478
Additional paid-in capital	41,920,116	41,920,116
Assignment of liabilities	(3,455,111)	(3,462,554)
Accumulated deficit	(45,132,434)	(45,293,649)
Total Stockholders' Deficiency	(6,655,001)	(6,823,659)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$ 0	$ 0

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, authorized	100,000,000	100,000,000
Preferred stock, issued	95,000,000	95,000,000
Preferred stock, outstanding	95,000,000	95,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, authorized	1,150,000,000	1,150,000,000
Common stock, issued	1,147,698,199	1,147,698,199
Common Stock, outstanding	1,147,698,199	1,147,698,199

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Expenses
General and administration	$ 98,699	$ 1,711,474
Selling and marketing	18,563	1,086
Operating loss	(117,262)	(1,712,560)
Interest and financing costs	(27,746)	(27,442)
Foreign exchange (loss) gain	306,223	(64,736)
Net Income (Loss)	$ 161,215	$ (1,804,738)
Basic and diluted net loss per share	$ 0	$ (0.00)
Weighted average shares used in calculating basic and diluted net loss per share	1,147,698,199	1,147,698,199

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' Deficiency Equity (Unaudited) - 3 months ended Mar. 31, 2020 - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Assignment Of Liabilities	Deficit Accumulated During the Development Stage	Total
Beginning balance at Dec. 31, 2019	$ 950	$ 11,478	$ 41,920,116	$ (3,462,554)	$ (45,293,649)	$ (6,823,659)
Beginning balance, Shares at Dec. 31, 2019	95,000,000	1,147,698,199
Cash settlement of liabilities				7,443		7,443
Net Loss					161,215	161,215
Ending balance at Mar. 31, 2020	$ 950	$ 11,478	$ 41,920,116	$ (3,455,111)	$ (45,132,434)	$ (6,655,001)
Ending balance, Shares at Mar. 31, 2020	95,000,000	1,147,698,199

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ 161,215	$ (1,804,738)
Adjustment to reconcile net loss to cash used in operating activities:
Stock based compensation		1,574,480
Interest and penalties	27,746	27,442
Unrealized foreign exchange loss (gain)	(310,231)	64,984
Changes in operating assets and liabilities:
Increase (decrease) in accounts payable and accrued liabilities	121,070	111,489
NET CASH USED IN OPERATING ACTIVITIES	(200)	(26,343)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from short term loans payable	200	26,343
NET CASH PROVIDED BY FINANCING ACTIVITIES	200	26,343
Effect of exchange rate changes on cash
NET (DECREASE) INCREASE IN CASH
CASH - END OF PERIOD
SUPPLEMENTAL CASH FLOW INFORMATION
Income tax paid
Interest paid
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Settlement of accounts payable by FE Pharmacy, Inc.	$ 7,443	$ 56,415

XML 16 R7.htm IDEA: XBRL DOCUMENT

BUSINESS AND GOING CONCERN

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS AND GOING CONCERN

NOTE 1 – BUSINESS AND GOING CONCERN

Organization

Kallo Inc. (“Kallo” or the “Company”) develops customized health care solutions designed to improve or enhance the delivery of care in the countries and regions we serve.

Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

ACCOUNTING POLICIES AND OPERATIONS

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

ACCOUNTING POLICIES AND OPERATIONS

NOTE 2 – ACCOUNTING POLICIES AND OPERATIONS

Basis of Presentation

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

XML 18 R9.htm IDEA: XBRL DOCUMENT

COMMON STOCK

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

COMMON STOCK

NOTE 3 – COMMON STOCK

During the three months ended March 31, 2020, there were no movements in share capital issued and outstanding.

XML 19 R10.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2020

RELATED PARTY TRANSACTIONS

NOTE 4 – RELATED PARTY TRANSACTIONS

Included in accounts payable and accrued liabilities is an amount of $1,310,980 (December 31, 2019 - $1,332,488) due to directors of the Company as of March 31, 2020.

Included in short term loans payable is an amount of $49,889 (December 31, 2019 - $49,758) due to the controlling shareholder of FE Pharmacy Inc. and a related party as at March 31, 2020.

XML 20 R11.htm IDEA: XBRL DOCUMENT

CONVERTIBLE LOANS PAYABLE

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

CONVERTIBLE LOANS PAYABLE

NOTE 5 – CONVERTIBLE LOANS PAYABLE

	March 31, 2020		December 31, 2019

Convertible promissory notes bearing interest at 15% per annum – third parties	$	271,412	$	265,217
Convertible promissory notes bearing interest at 15% per annum – related parties		928,683		907,132
	$	1,200,095	$	1,172,349

XML 21 R12.htm IDEA: XBRL DOCUMENT

SHORT TERM LOANS PAYABLE

3 Months Ended

Mar. 31, 2020

Short-term Debt, Other Disclosures [Abstract]

SHORT TERM LOANS PAYABLE

NOTE 6 – SHORT TERM LOANS PAYABLE

	March 31, 2020		December 31, 2019

Non-interest bearing short term funding from third party	$	15,347	$	16,763
Non-interest bearing short term funding from related party		49,889		49,758
	$	65,236	$	66,521

XML 22 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Contingencies

On October 24, 2016, a consultant obtained a judgement ordering Kallo to pay Canadian $34,924 for unpaid fees. The full amount has been accrued for in the financial statements of Kallo.

Responsibility for payments of the above claims has been assumed by FE Pharmacy Inc. under the terms of the agreement mentioned in Note 3.

XML 23 R14.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2020

Subsequent Events

SUBSEQUENT EVENTS

NOTE 8 – SUBSEQUENT EVENTS

XML 24 R15.htm IDEA: XBRL DOCUMENT

ACCOUNTING POLICIES AND OPERATIONS (Policies)	3 Months Ended
ACCOUNTING POLICIES AND OPERATIONS (Policies)	Mar. 31, 2020
Accounting Policies And Operations
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X related to smaller reporting companies. These unaudited consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes, which are included as part of the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year ended December 31, 2019 as reported in the 10-K have been omitted. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation, have been included in the accompanying unaudited consolidated financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires the use of a new current expected credit loss (“CECL”) model in estimating allowances for doubtful accounts with respect to accounts receivable. Receivables from revenue transactions, or trade receivables, are recognized when the corresponding revenue is recognized under ASC Topic 606, Revenue from Contracts with Customers. The CECL model requires that the Company estimate its lifetime expected credit loss with respect to these receivables and record allowances that when deducted from the balance of the receivables, represent the estimated net amounts expected to be collected. Given the generally short term nature of trade receivables, we do not apply a discounted cash flow methodology. However, the Company considers whether historical loss rates are consistent with expectations of forward-looking estimates for our trade receivables. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements On December 18, 2019 the FASB issued the ASU 2019-12 “Income taxes (Topic 740)—Simplifying the accounting for income taxes”. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is assessing the effects that the adoption of this accounting pronouncement may have on its financial statements.

XML 25 R16.htm IDEA: XBRL DOCUMENT

CONVERTIBLE LOANS PAYABLE (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Summary of convertible loans payable

	March 31, 2020		December 31, 2019

Convertible promissory notes bearing interest at 15% per annum – third parties	$	271,412	$	265,217
Convertible promissory notes bearing interest at 15% per annum – related parties		928,683		907,132
	$	1,200,095	$	1,172,349

XML 26 R17.htm IDEA: XBRL DOCUMENT

SHORT TERM LOANS PAYABLE (Tables)

3 Months Ended

Mar. 31, 2020

Short-term Debt, Other Disclosures [Abstract]

Summary of short term loans payable

	March 31, 2020		December 31, 2019

Non-interest bearing short term funding from third party	$	15,347	$	16,763
Non-interest bearing short term funding from related party		49,889		49,758
	$	65,236	$	66,521

XML 27 R18.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)	12 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative)	Dec. 31, 2019 USD ($) shares
Related Party Transactions
Shares issued to directors and employees \| $	$ 1,373,700
Shares issued to directors and employees, Shares \| shares	57,000,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

CONVERTIBLE LOANS PAYABLE (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Convertible loans payable	$ 1,200,095	$ 1,172,349
Convertible promissory notes bearing interest at 15% per annum - third party
Convertible loans payable	271,412	265,217
Convertible promissory notes bearing interest at 15% per annum - related parties
Convertible loans payable	$ 928,683	$ 907,132

XML 29 R20.htm IDEA: XBRL DOCUMENT

CONVERTIBLE LOANS PAYABLE (Details Narrative) - USD ($)	3 Months Ended
CONVERTIBLE LOANS PAYABLE (Details Narrative) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible loans payable	$ 1,200,095		$ 1,172,349
Interest and Financing Cost	$ 27,746	$ 27,442

XML 30 R21.htm IDEA: XBRL DOCUMENT

SHORT TERM LOANS PAYABLE (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Short term loans payable	$ 65,236	$ 66,521
Non-interest bearing short term funding from third parties
Short term loans payable	15,347	16,431
Non-interest bearing short term funding from related parties
Short term loans payable	$ 49,889	$ 49,758

XML 31 R22.htm IDEA: XBRL DOCUMENT

SHORT TERM LOANS PAYABLE (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Short-term Debt, Other Disclosures [Abstract]
Short term loans payable	$ 65,236	$ 66,521

EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 33 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 29 163 1 false 9 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://kalloinc.ca/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://kalloinc.ca/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) Sheet http://kalloinc.ca/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) (Unaudited) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://kalloinc.ca/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficiency Equity (Unaudited) Sheet http://kalloinc.ca/role/StatementsOfChangesInStockholdersDeficiencyEquity Consolidated Statements of Changes in Stockholders' Deficiency Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://kalloinc.ca/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - BUSINESS AND GOING CONCERN Sheet http://kalloinc.ca/role/BusinessAndGoingConcern BUSINESS AND GOING CONCERN Notes 7 false false R8.htm 00000008 - Disclosure - ACCOUNTING POLICIES AND OPERATIONS Sheet http://kalloinc.ca/role/AccountingPoliciesAndOperations ACCOUNTING POLICIES AND OPERATIONS Notes 8 false false R9.htm 00000009 - Disclosure - COMMON STOCK Sheet http://kalloinc.ca/role/CommonStock COMMON STOCK Notes 9 false false R10.htm 00000010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://kalloinc.ca/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - CONVERTIBLE LOANS PAYABLE Sheet http://kalloinc.ca/role/ConvertibleLoansPayable CONVERTIBLE LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - SHORT TERM LOANS PAYABLE Sheet http://kalloinc.ca/role/ShortTermLoansPayable SHORT TERM LOANS PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://kalloinc.ca/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://kalloinc.ca/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - ACCOUNTING POLICIES AND OPERATIONS (Policies) Sheet http://kalloinc.ca/role/AccountingPoliciesAndOperationsPolicies ACCOUNTING POLICIES AND OPERATIONS (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - CONVERTIBLE LOANS PAYABLE (Tables) Sheet http://kalloinc.ca/role/ConvertibleLoansPayableTables CONVERTIBLE LOANS PAYABLE (Tables) Tables http://kalloinc.ca/role/ConvertibleLoansPayable 16 false false R17.htm 00000017 - Disclosure - SHORT TERM LOANS PAYABLE (Tables) Sheet http://kalloinc.ca/role/ShortTermLoansPayableTables SHORT TERM LOANS PAYABLE (Tables) Tables http://kalloinc.ca/role/ShortTermLoansPayable 17 false false R18.htm 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://kalloinc.ca/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://kalloinc.ca/role/RelatedPartyTransactions 18 false false R19.htm 00000019 - Disclosure - CONVERTIBLE LOANS PAYABLE (Details) Sheet http://kalloinc.ca/role/ConvertibleLoansPayableDetails CONVERTIBLE LOANS PAYABLE (Details) Details http://kalloinc.ca/role/ConvertibleLoansPayableTables 19 false false R20.htm 00000020 - Disclosure - CONVERTIBLE LOANS PAYABLE (Details Narrative) Sheet http://kalloinc.ca/role/ConvertibleLoansPayableDetailsNarrative CONVERTIBLE LOANS PAYABLE (Details Narrative) Details http://kalloinc.ca/role/ConvertibleLoansPayableTables 20 false false R21.htm 00000021 - Disclosure - SHORT TERM LOANS PAYABLE (Details) Sheet http://kalloinc.ca/role/ShortTermLoansPayableDetails SHORT TERM LOANS PAYABLE (Details) Details http://kalloinc.ca/role/ShortTermLoansPayableTables 21 false false R22.htm 00000022 - Disclosure - SHORT TERM LOANS PAYABLE (Details Narrative) Sheet http://kalloinc.ca/role/ShortTermLoansPayableDetailsNarrative SHORT TERM LOANS PAYABLE (Details Narrative) Details http://kalloinc.ca/role/ShortTermLoansPayableTables 22 false false All Reports Book All Reports kalo-20200331.xml kalo-20200331.xsd kalo-20200331_cal.xml kalo-20200331_def.xml kalo-20200331_lab.xml kalo-20200331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 37 0001520138-21-000140-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-21-000140-xbrl.zip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
VX9G%7LX&[(+J;%N4E["!$WJR4I!0-V8Y& M6YIU$H\>$X^/*<2Y-&?*:\CTQ;!/V]:U(SRAGNLYWTN0UP<6SYWJ^19B'+K/&$47 M<+]!/"&B$_E".?#YZF5Y&U[N8$;41N-W:)6K1ZKID?.]_07RY2,+9D=>__K1 M0<^=/&N)Z-M4RK>IE&]3*=^F4KY-I0QWWW/JZ9-J41M&5=!P765L6\LK !K86QO+3(P M,C P,S,Q+GAS9%!+ 0(4 Q0 ( !B48E(=#;R/2 @ +A, 5 M " <&UL4$L! A0#% @ &)1B4HZ=+45)( @K$! !4 M ( !PD0 &MA;&\M,C R,# S,S%?;&%B+GAM;%!+ 0(4 Q0 ( !B4 M8E)#BR7]VQ4 !!% 0 5 " 3YE !K86QO+3(P,C P,S,Q >7W!R92YX;6Q02P4& 8 !@"* 0 3'L end